There are 2 clinical trials
The aim is to be able to predict the hormonal response according to gonadotropin receptor genotype and hormone type used for treatment of women undergoing in vitro fertilization or egg donation. Outcome will be measured as pregnancy success, live born babies and unwanted side effects.
This assumption is supported by a recent study on more than 600 women undergoing in vitro fertilization, demonstrating that whereas only 10% of women with asparagine in both genes (FSHR N680S and LHR N312S) became pregnant, 40% of those with serine did (Lindgren I et al. --- N680S --- --- N312S ---
Description: Association between pregnancy rate and genotype is evaluated
Measure: Pregnancy Time: up to 12 months after treatmentDescription: Number of eggs developed in response to drug according to genotype is measured
Measure: Number of oocytes Time: up to 6 months after treatmentDescription: Live birth rate according to genotype is analyzed
Measure: live birth Time: up to 12 months after treatmentDescription: Association between overreaction to hormonal stimulation and genotype is analysed
Measure: Ovarian hyper stimulation syndrome Time: Up to 6 months after treatmentDescription: No or poor development of eggs in response to drug is analysed, genotype taken into account
Measure: Poor response Time: Up to 6 months after treatmentAim of study: To compare the relationship between serum AMH and ovarian response for IVF with the GnRH antagonist protocol in patients who are carriers of FSH and/or LH receptor polymorphisms with those that are not.
To define the incidence of carriers of polymorphisms in the FSH receptor (FSHR) variant N680S (homozygous and heterozygous) among women undergoing ovarian stimulation for IVF.. polymorphisms in the LH receptor (LHR) variant N312S. --- N680S --- --- N312S ---
To define the incidence of carriers of polymorphisms in the LH receptor (LHR) variant N312S (homozygous and heterozygous) among women undergoing ovarian stimulation for IVF.. Doses of gonadotrophin needed and polymorphisms. --- N312S ---
Description: To compare the relationship between serum AMH and ovarian response for IVF with the GnRH antagonist protocol in patients who are carriers of FSH and/or LH receptor polymorphisms with those that are not.
Measure: Gonadotrophin receptor polymorphisms and ovarian response and AMH value Time: 1 yearDescription: To define the incidence of carriers of polymorphisms in the FSH receptor (FSHR) variant N680S (homozygous and heterozygous) among women undergoing ovarian stimulation for IVF.
Measure: polymorphisms in the FSH receptor (FSHR) variant N680S Time: 1 yearDescription: To define the incidence of carriers of polymorphisms in the LH receptor (LHR) variant N312S (homozygous and heterozygous) among women undergoing ovarian stimulation for IVF.
Measure: polymorphisms in the LH receptor (LHR) variant N312S Time: 1 yearDescription: To analyse the doses of gonadotrophins needed for stimulation on each group of patients
Measure: Doses of gonadotrophin needed and polymorphisms Time: 1 year